-+ 0.00%
-+ 0.00%
-+ 0.00%

Rein Therapeutics prices 50 million-share follow-on offering at $1 per share

PUBT·05/01/2026 00:00:16
Listen to the news
Rein Therapeutics prices 50 million-share follow-on offering at $1 per share
  • Rein Therapeutics priced an underwritten public offering of 50 million common shares at USD 1 per share for gross proceeds of USD 50 million.
  • Underwriters received a 45-day option to buy up to 7.5 million additional shares to cover over-allotments.
  • Deal expected to close May 4, 2026.
  • Konik Capital Partners is sole book-running manager.
  • Net proceeds earmarked to fund Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis through completion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604302000PRIMZONEFULLFEED9711157) on May 01, 2026, and is solely responsible for the information contained therein.